Bora CDMO Bora CDMO

X

Find the latest Drugs in Development and Pipeline Prospector News of Neuropore Therapies.

  • Webinars & Exhibitions

PharmaCompass
Send me more info on How To Grow My Bussiness Digitally?
Neuropore Therapies
United_States_of_America Flag
Country
Country
U.S.A
Address
Address
10835 Road to the Cure, Suite 230 San Diego, CA 92121
Telephone
Telephone
(858) 273-1831
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Details:

The grant will be used to support the preclinical and clinical development a of a novel brain-penetrating small molecule NPT1220-478, Toll-Like receptor 2 antagonist and maintaining a harmful neuro- inflammatory condition in Parkinson’s disease.


Lead Product(s): NPT1220-478

Therapeutic Area: Neurology Product Name: NPT1220-478

Highest Development Status: PreclinicalProduct Type: Small molecule

Partner/Sponsor/Collaborator: Michael J. Fox Foundation for Parkinson’s Research

Deal Size: $4.8 million Upfront Cash: Undisclosed

Deal Type: Funding April 19, 2022

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

UCB0599 is an orally administered small molecule alpha-synuclein misfolding inhibitor arising from a Collaboration entered into between Neuropore Therapies and UCB Biopharma on December, 2014. This milestone payment is a result of the continued clinical progress of UCB0599.


Lead Product(s): UCB0599

Therapeutic Area: Neurology Product Name: UCB0599

Highest Development Status: Phase IIProduct Type: Small molecule

Partner/Sponsor/Collaborator: UCB Pharma S.A

Deal Size: $460.0 million Upfront Cash: Undisclosed

Deal Type: Collaboration May 17, 2021

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

The funding will support the preclinical evaluation and development of Neuropore's leading Toll-Like Receptor 2 (TLR2) antagonist NPT1220-312 for the treatment of amyotrophic lateral sclerosis.


Lead Product(s): NPT1220-312

Therapeutic Area: Neurology Product Name: Undisclosed

Highest Development Status: PreclinicalProduct Type: Undisclosed

Partner/Sponsor/Collaborator: ALS Association

Deal Size: $0.5 million Upfront Cash: Undisclosed

Deal Type: Funding February 17, 2020

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

The Phase 1 study was designed to evaluate the safety, tolerability and pharmacokinetics of single and multiple doses of NPT520-34.


Lead Product(s): NPT520-34

Therapeutic Area: Neurology Product Name: NPT520-34

Highest Development Status: Phase IProduct Type: Small molecule

Partner/Sponsor/Collaborator: Celerion

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 13, 2020

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty
Post Enquiry
POST ENQUIRY